المؤلفون: H. Kievit, M.B. Muntinghe-Wagenaar, L.B.M. Hijmering-Kappelle, B.I. Hiddinga, J.F. Ubbels, R. Wijsman, G. Slingers, R. de Vries, H.J.M Groen, H.A.M. Kerstjens, A.J. van der Wekken, T.J.N. Hiltermann

المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC), Translational Immunology Groningen (TRIGR)

المصدر: Lung Cancer, 178, 96-102. ELSEVIER IRELAND LTD

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Cancer Research, Oncology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6809a4ef5dd9af352c7e9aaec1fc9fc9Test
https://hdl.handle.net/11370/ffe0eead-b14e-4383-9522-35c69b24b3ccTest

المؤلفون: Betzabel N. Cajiao Garcia, Léon C. van Kempen, Chantal C.H.J. Kuijpers, Ed Schuuring, Stefan M. Willems, Anthonie J. van der Wekken

المساهمون: Targeted Gynaecologic Oncology (TARGON), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Lung Cancer, 167, 1-7. ELSEVIER IRELAND LTD

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, endocrine system diseases, CELL LUNG-CANCER, EGFR, KRAS p, ONCOGENE, Sotorasib, FREQUENCY, Proto-Oncogene Proteins p21(ras), Predictive biomarkers, Carcinoma, Non-Small-Cell Lung, Prevalence, KRAS, (G12C), Molecular diagnostics, Humans, neoplasms, Netherlands, Retrospective Studies, MUTATIONS, MEDICINE, ADENOCARCINOMA, digestive system diseases, respiratory tract diseases, Non-Small Cell Lung Cancer, Oncology, SURVIVAL, INHIBITORS, K-RAS

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4326172768ae05bf38490aea7043ecaTest
https://hdl.handle.net/11370/429b5ee5-98cf-4d71-8b3a-d53796a7252cTest

المؤلفون: Elisabeth M.P. Steeghs, Harry J.M. Groen, Ed Schuuring, Mieke J. Aarts, Ronald A.M. Damhuis, Quirinus J.M. Voorham, Marjolijn J.L. Ligtenberg, Katrien Grünberg

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON)

المصدر: Lung Cancer, 167, pp. 87-97
Lung Cancer, 167, 87-97
Lung Cancer, 167, 87-97. ELSEVIER IRELAND LTD

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Proto-Oncogene Proteins B-raf, Cancer Research, Lung Neoplasms, Mutation/genetics, Carcinoma, Non-Small-Cell Lung/drug therapy, ErbB Receptors/genetics, Carcinoma, Non-Small-Cell Lung/drug therapy, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Adenocarcinoma, Protein-Tyrosine Kinases, ErbB Receptors, Proto-Oncogene Proteins/therapeutic use, Oncology, Squamous Cell, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Mutation, Carcinoma, Squamous Cell, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Humans, Lung Neoplasms/drug therapy

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8724fa1228e304196d51c5a8a86793Test
https://doi.org/10.1016/j.lungcan.2022.04.001Test

المؤلفون: Robert Peric, Vincent van der Noort, Harry J.M. Groen, Anne-Marie C. Dingemans, Nico van Walree, Franz M.N.H. Schramel, Christi M.J. Steendam, Pepijn Brocken, Stijn L.W. Koolen, G.D. Marijn Veerman, John W. G. van Putten, Ron H.J. Mathijssen, Egbert F. Smit, Joachim G.J.V. Aerts, Magdolen Youssef

المساهمون: Pulmonary Medicine, Medical Oncology, Pharmacy, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE)

المصدر: Lung Cancer, 160, 44-49. Elsevier Ireland Ltd
Lung Cancer, 160, 44-49. ELSEVIER IRELAND LTD

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Erlotinib Hydrochloride/therapeutic use, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Combination therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Quinazolines/therapeutic use, Taxoids/therapeutic use, EGFR, Non-Small-Cell Lung/drug therapy, Docetaxel, Gastroenterology, Disease-Free Survival, Erlotinib Hydrochloride, SDG 3 - Good Health and Well-being, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, Progression-free survival, Epidermal growth factor receptor, CANCER PATIENTS, Lung Neoplasms/drug therapy, COMBINATION, neoplasms, SCHEDULE, Docetaxel/therapeutic use, biology, PLASMA, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Hazard ratio, CHEMOTHERAPY, medicine.disease, Oncology, Erlotinib, Toxicity, biology.protein, Quinazolines, Taxoids, business, Non-small-cell lung cancer, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f1412cde3a5dc0bde1bb210d253e089Test
https://doi.org/10.1016/j.lungcan.2021.08.002Test

المؤلفون: Quirinus J. M. Voorham, Chantal C H J Epskamp-Kuijpers, Bregje M Koomen, Stefan M. Willems, Carmen van Dooijeweert, Ivette A. G. Deckers, Anne S R van Lindert

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE)

المصدر: Lung Cancer, 159, 117-126. ELSEVIER IRELAND LTD

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, EXPRESSION, Cancer Research, medicine.medical_specialty, Lung Neoplasms, NSCLC, BREAST, B7-H1 Antigen, Non-small cell lung cancer, Internal medicine, Cytology, Carcinoma, Non-Small-Cell Lung, medicine, Biomarkers, Tumor, Cutoff, Humans, ASSAY, Programmed death-ligand 1, Lung cancer, Clinical pathology, business.industry, medicine.disease, Immunohistochemistry, Confidence interval, Interlaboratory variation, VARIABILITY, CYTOPATHOLOGY, Oncology, Cytopathology, Cohort, BLOCK, Non small cell, business, CONCORDANCE

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93284a2cde17c2f4d313693bce96e273Test
https://doi.org/10.1016/j.lungcan.2021.07.012Test

المؤلفون: Ronald A M Damhuis, A.L. Noordhof, Ben J.W. Venmans, A.J. de Langen, W. H. van Geffen, Wim Timens, Lizza E.L. Hendriks

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9)

المصدر: Lung Cancer, 155, 163-169. ELSEVIER IRELAND LTD
Lung Cancer, 155, 163-169. Elsevier Ireland Ltd

مصطلحات موضوعية: 0301 basic medicine, Oncology, Mono-immunotherapy, Cancer Research, Lung Neoplasms, Pembrolizumab, medicine.disease_cause, THERAPY, B7-H1 Antigen, 0302 clinical medicine, Non-small cell lung cancer, Carcinoma, Non-Small-Cell Lung, Lung, Netherlands, DOCETAXEL, education.field_of_study, Protein-Tyrosine Kinases, Kirsten rat sarcoma, Prognosis, CANCER, medicine.anatomical_structure, 030220 oncology & carcinogenesis, SURVIVAL, Adenocarcinoma, KRAS, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Population, Antibodies, Monoclonal, Humanized, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Internal medicine, medicine, Adenocarcinoma of the lung, ROS1, Humans, education, Retrospective Studies, business.industry, medicine.disease, PREDICTIVE-VALUE, EFFICACY, digestive system diseases, Cancer registry, 030104 developmental biology, Mutation, business, INHIBITORS

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38ffe4ede24f117a3e2a1ead344f5614Test
https://doi.org/10.1016/j.lungcan.2021.04.001Test

المؤلفون: Reinoud Gosens, Frank A.E. Kruyt, Coby Meijer, Win Sen Heng, Shiau-Chuen Cheah, Milind Pore, T. Jeroen N. Hiltermann

المساهمون: Translational Immunology Groningen (TRIGR), Molecular Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE)

المصدر: Lung Cancer, 154, 13-22. ELSEVIER IRELAND LTD

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, Stem cell marker, Flow cytometry, 03 medical and health sciences, 0302 clinical medicine, SOX2, Cancer stem cell, Cell Line, Tumor, Humans, Medicine, medicine.diagnostic_test, biology, business.industry, CD44, Small Cell Lung Carcinoma, carbohydrates (lipids), Hyaluronan Receptors, 030104 developmental biology, Oncology, Cell culture, 030220 oncology & carcinogenesis, Disease Progression, Neoplastic Stem Cells, biology.protein, Cancer research, Stem cell, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4061720a2c1d76a75a51bc775f4fba59Test
https://doi.org/10.1016/j.lungcan.2021.02.002Test

المؤلفون: Peter J. van der Spek, Harry J.M. Groen, Maureen Los, Anouk van Schetsen, Bram van Es, T. Jeroen N. Hiltermann, Daan P. Hurkmans, Joachim G.J.V. Aerts, Rogier T A van Wijck, Thu Vu, Tjebbe Tauber, Wouter Karman, Menno Tamminga, Sissy Chen, Ed Schuuring, Tom Peters

المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Translational Immunology Groningen (TRIGR), Internal Medicine, Pathology, Pulmonary Medicine

المصدر: Lung Cancer, 146, 341-349. ELSEVIER IRELAND LTD
Lung Cancer, 146, 341-349. Elsevier Ireland Ltd

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, Lung Neoplasms, Microenvironment, Adenocarcinoma of Lung, Adenocarcinoma, NSCLC, Methylation, 03 medical and health sciences, 0302 clinical medicine, Immune system, SDG 3 - Good Health and Well-being, Carcinoma, Non-Small-Cell Lung, Squamous cell carcinoma, REVEALS, medicine, Humans, Epigenetics, Lung cancer, Gene, business.industry, DNA, DNA Methylation, medicine.disease, Phenotype, Gene Expression Regulation, Neoplastic, Immune gene, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, DNA methylation, Cancer research, BIOPSY, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7cad2da1748ee650f7ecd47862da0b8Test
https://doi.org/10.1016/j.lungcan.2020.06.008Test

المؤلفون: Smit, H.J.M., Aerts, J., Heuvel, M. van den, Hiltermann, T.J.N., Bahce, I., Smit, E.F., Dingemans, A.M.C., Hendriks, L.E., Stigt, J.A., Schramel, F.M.N.H., Tinteren, H. van, Groen, H.J.M., NVALT Immunotherapy Register

المساهمون: Pulmonary medicine, CCA - Cancer biology and immunology, Pulmonary Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Translational Immunology Groningen (TRIGR)

المصدر: Lung Cancer, 140, 107-112
On behalf of all participants of NVALT Immunotherapy Register (see addendum) 2020, ' Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry ', Lung Cancer, vol. 140, pp. 107-112 . https://doi.org/10.1016/j.lungcan.2019.12.011Test
Lung Cancer, 140, 107-112. ELSEVIER IRELAND LTD
Lung Cancer, 140, 107-112. Elsevier Ireland Ltd
Lung Cancer, 140, pp. 107-112

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Disease, THERAPY, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Registries, Immune Checkpoint Inhibitors, Netherlands, Response rate (survey), Aged, 80 and over, DOCETAXEL, Brain Neoplasms, Middle Aged, Prognosis, Survival Rate, Oncology, Docetaxel, 030220 oncology & carcinogenesis, SAFETY, Carcinoma, Squamous Cell, Population study, Female, Immunotherapy, Nivolumab, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Underrepresented population, Adenocarcinoma of Lung, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 03 medical and health sciences, ADVANCED MELANOMA, SDG 3 - Good Health and Well-being, Internal medicine, ANTI-PD-1, medicine, Humans, Check point inhibitors, Lung cancer, Aged, business.industry, NIVOLUMAB, medicine.disease, Small Cell Lung Carcinoma, Clinical trial, 030104 developmental biology, Advanced non-small cell lung cancer, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df54b78407484fea5bcc5b5a33e209dTest
https://hdl.handle.net/11370/42ee32f5-cbb6-413f-9e30-68f16de58812Test

المؤلفون: Egbert F. Smit, Buge Oz, Lukas Bubendorf, Stephen P. Finn, Lukas C. Heukamp, M. van den Heuvel, I. Marondel, A.O Grady, John R. Gosney, Anders Mellemgaard, Fabrice Duplaquet, Idris Bahce, Sayed M.S. Hashemi, Birgit Weynand, Xavier Durando, S.M.S. Samii, Patrick Pauwels, Pieter E. Postmus, Kim Monkhorst, Frédérique Penault-Llorca, S. Duin, Monika G. Looijen-Salamon, M.A. van der Drift, Ernst-Jan M. Speel, Wim Timens, Reinhard Buettner, N. Akyurek, Birgit I. Lissenberg-Witte, Erik Thunnissen, Birgit Guldhammer Skov, Ed Schuuring, Jens Benn Sørensen, Juergen Wolf, A.J. de Langen, Anne-Marie C. Dingemans

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MORF - Pôle de Morphologie, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service de pneumologie, Pathology, Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pulmonary medicine

المصدر: Lung cancer: journal of the International Association for the Study of Lung Cancer
Lung Cancer, 138, pp. 13-18
Lung Cancer, 138, 13-18
Lung Cancer
Lung Cancer, 138, 13-18. ELSEVIER IRELAND LTD
Thunnissen, E, Lissenberg-Witte, B I, van den Heuvel, M M, Monkhorst, K, Skov, B G, Sørensen, J B, Mellemgaard, A, Dingemans, A M C, Speel, E J M, de Langen, A J, Hashemi, S M S, Bahce, I, van der Drift, M A, Looijen-Salamon, M G, Gosney, J, Postmus, P E, Samii, S M S, Duplaquet, F, Weynand, B, Durando, X, Penault-Llorca, F, Finn, S, Grady, A O, Oz, B, Akyurek, N, Buettner, R, Wolf, J, Bubendorf, L, Duin, S, Marondel, I, Heukamp, L C, Timens, W, Schuuring, E M D, Pauwels, P & Smit, E F 2019, ' ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib ', Lung Cancer, vol. 138, pp. 13-18 . https://doi.org/10.1016/j.lungcan.2019.09.023Test
Lung Cancer, 138, 13-18. Elsevier Ireland Ltd
Lung cancer, Vol. 138, p. 13-18 (2019)

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, INTERNATIONAL-ASSOCIATION, Stress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13], 0302 clinical medicine, alk, Non-small cell lung cancer, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Prospective Studies, In Situ Hybridization, Fluorescence, Gene Rearrangement, fluorescence in situ hybridisation, medicine.diagnostic_test, treatment, REARRANGEMENT, Middle Aged, OF-AMERICAN-PATHOLOGISTS, Prognosis, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3], Immunohistochemistry, PREVALENCE, Survival Rate, LUNG-CANCER PATIENTS, Treatment Outcome, 030220 oncology & carcinogenesis, immunohistochemistry, Fish , Female, Non small cell, medicine.drug, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 03 medical and health sciences, MOLECULAR TESTING GUIDELINE, All institutes and research themes of the Radboud University Medical Center, Crizotinib, Internal medicine, Biopsy, medicine, Humans, Protein Kinase Inhibitors, non-small cell lung cancer, business.industry, ADENOCARCINOMA, Treatment, 030104 developmental biology, COPY NUMBER, ALK, KINASE INHIBITORS GUIDELINE, Fluorescence in situ hybridisation, Human medicine, prognosis, business, Stage iv, Fluorescence in situ hybridization, IHC

وصف الملف: pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fbd4c2857be1034f64d88d9f7a78b17Test
https://doi.org/10.1016/j.lungcan.2019.09.023Test